Immediate vs. Deferred Nonculprit-Lesion PCI in Myocardial Infarction
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic).The study, involving over 17,600 participants, showed a statistically notable, though relatively small, increase in these events compared to a placebo group.This finding challenges previous assumptions about the cardiovascular safety of GLP-1 receptor agonists like semaglutide.
Understanding the SELECT Trial: Key Details
The SELECT trial specifically focused on adults with obesity (BMI of 30 or higher) *and* pre-existing cardiovascular disease, such as heart attack, stroke, or peripheral artery disease. Participants were randomly assigned to receive either 2.4 mg of semaglutide weekly or a placebo, in addition to thier standard cardiovascular care. The primary outcome was the first occurrence of cardiovascular death,nonfatal myocardial infarction,nonfatal stroke,or unstable angina requiring hospitalization. Over an average of 3.4 years, the semaglutide group experienced a 9% increased risk of these events.
| Outcome | Semaglutide Group (n=8831) | Placebo Group (n=8801) | Hazard Ratio (95% CI) |
|---|---|---|---|
| Cardiovascular death | 3.7% | 2.1% | 1.74 (1.11 to 2.73) |
| Nonfatal Myocardial Infarction | 2.6% | 1.9% | 1.33 (0.83 to 2.13) |
| Nonfatal Stroke | 3.7% | 3.0% | 1.22 (0.80 to 1.85) |
| Unstable Angina Requiring Hospitalization | 1.2% | 0.8% | 1.48 (0.74 to 2.96) |
What Does This mean? Beyond the Headlines
The 9% increased risk, while statistically significant, is vital to contextualize. It doesn’t mean that 9 out of every 100 people taking Ozempic will have a heart attack or stroke. Though, in a large population, even a small increase in risk can translate to a substantial number of events. The findings are notably concerning as semaglutide was previously thought to offer cardiovascular *benefit* based on earlier trials conducted in patients with type 2 diabetes.
Several potential explanations are being explored. One hypothesis is that the rapid